The National Institutes of Health, National Institute of General Medical Sciences, is accepting applications for Limited Competition: Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 – Clinical Trial Not Allowed), opportunity PAR-27-054, Assistance Listing 93.859.
COBRE-D supports institutions in IDeA jurisdictions that need to build biomedical research capacity in a broad scientific area that is strategically important to the institution but currently lacks sufficient infrastructure or expertise. The five-year program supports investigator recruitment and development, research facilities, research administration, and optional research cores.
Next application deadline: September 25, 2026 at 5:00 PM local time of the applicant organization. Additional receipt dates recur on January 25, May 25, and September 25 through May 25, 2029. Application budgets are limited to $400,000 in direct costs during year 1 and $1.8 million in annual direct costs during years 2 through 5, for a maximum potential five-year direct-cost request of $7.6 million. No cost sharing is required.
Eligible applicants are public and private higher-education institutions and nonprofit organizations in IDeA jurisdictions: Alaska, Arkansas, Delaware, Hawaii, Idaho, Kansas, Kentucky, Louisiana, Maine, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, Puerto Rico, Rhode Island, South Carolina, South Dakota, Vermont, West Virginia, and Wyoming. At the time of submission the applicant institution must have no active COBRE grants, including awards in no-cost extension. Only one COBRE-D application per institution is allowed.
Required registrations include SAM.gov/UEI, Grants.gov, eRA Commons, and ORCID for PDs/PIs. Applications are submitted through NIH ASSIST or an eligible institutional system-to-system solution to Grants.gov and tracked in eRA Commons. The PD/PI must be an established biomedical research scientist with appropriate mentoring and administrative experience and an active, peer-reviewed, externally funded research grant in the same general scientific area.
Clinical trials are not allowed. The program may fund research facilities, equipment purchases, instrumentation modernization, and optional research cores. Limited alterations and renovations may be requested up to $300,000 during years 2 and/or 3. A legitimate role for the Nonagon N9+ device and platform exists only where an eligible institution’s proposed biomedical scientific area needs shared non-interventional physiological measurement, guided examination, remote or telehealth-enabled observational research, translational data capture, or related capabilities.
Atlas assigns an Atlas Opportunity Score of 86/100 and an N9+ Fit Score of 74/100. The fit is conditional because COBRE-D is intentionally broad and the scientific focus is institution-specific. Dr. Miltie, LLC is not eligible to serve as the prime applicant, so any role would be partner- or vendor-led under the eligible institution’s approved program and procurement rules.